Pilot Study of Vardenafil and Carboplatin in Patients With Gliomas and Brain Metastases

• Status: Terminated
• Trial end date: 2016-02-11
• Target enrollment: 0
• Participant gender: All

Summary

This is a randomized pilot study to investigate the ability of a phosphodiesterase-V inhibitor (vardenafil) to increase the concentration of systemically delivered chemotherapy, carboplatin, in patients with recurrent malignant gliomas or metastatic brain cancer. This study will also determine the toxicity and tolerability of a phosphodiesterase-V inhibitor (vardenafil) in combination with intravenous carboplatin for patients with recurrent malignant gliomas or metastatic brain cancer.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cedars-Sinai Medical Center
• Treatments: Carboplatin; Vardenafil Dihydrochloride

Criteria

Inclusion Criteria:

• Patients with recurrent malignant glioma or metastatic brain cancer requiring craniotomy for gross total resection, subtotal resection or biopsy

• Previously histopathologically proven glioma or radiographic appearance of metastatic lesion with a primary neoplasm that is known to metastasize to the brain

• Patients must have a Karnofsky performance status ≥ 60% (i.e. the patient must be able to care for himself/herself with occasional help from others)

• Patients must have normal hematologic, renal and liver function (i.e. Hemoglobin >10 gm/dl, Absolute neutrophil count ≥ 1500/mm3, Platelets ≥ 100,000/mm3, creatinine ≤ 1.5 mg/dl or Cr Clearance ≥ 60 mL/min, total bilirubin ≤ 1.5 mg/dl, transaminases ≤ 4 times above the upper limits of the institutional normal.

• Patients must be able to provide written informed consent

Exclusion Criteria:

• Patients with serious concurrent infection or medical illness, which would jeopardize the ability of the patient to receive the treatment outlined in this protocol with reasonable safety

• Patients who are pregnant or breast-feeding

• Patients receiving concurrent therapy for their tumor (i.e. chemotherapeutics or investigational agents)

• Allergy to 5HT-(3) receptor antagonist including tropisetron, ondansetron

• Patients on enzyme-inducing anticonvulsants (Dilantin, Tegretol, Phenobarbital)

• Patients with unstable angina or serious cardiovascular disease

• Known HIV positivity or AIDS-related illness

• History of allergic reaction to platinum compounds or mannitol

• Medical conditions requiring the use of oral nitrates

• Patients on alpha-1 adrenergic blockers